Summit Therapeutics Inc. announced data from the HARMONi-2 trial and the Phase II trial AK112-205 at the WCLC 2024 conference, showcasing results from various cancer studies sponsored by Akeso, Inc.
AI Assistant
SUMMIT THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.